Precision BioSciences announces presentation from PBGENE-HBV study

Precision BioSciences (DTIL) “announced a late-breaking oral presentation at the American Association for the Study of Liver Diseases The Liver Meeting(R) 2025. The presentation includes data from the ongoing ELIMINATE-B Phase 1 study evaluating PBGENE-HBV, a first-in-class in vivo gene editing therapy designed to eliminate cccDNA, the root cause of chronic Hepatitis B, and inactivate integrated HBV DNA. The presentation, to be delivered by Dr. Man-Fung Yuen, Chair Professor of Gastroenterology and Hepatology at The University of Hong Kong, features new data from nine patients across 22 doses in the first three cohorts of the ELIMINATE-B trial.”